J. Goldman & Co’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-168,778
| Closed | -$562K | – | 385 |
|
|
2019
Q4 | $562K | Buy |
+168,778
| New | +$537K | 0.04% | 212 |
|
|
2019
Q3 | – | Sell |
-100,000
| Closed | -$238K | – | 412 |
|
|
2019
Q2 | $238K | Sell |
100,000
-789,000
| -89% | -$2.36M | 0.02% | 246 |
|
|
2019
Q1 | $3.33M | Buy |
+889,000
| New | +$3.33M | 0.19% | 136 |
|
|
2018
Q4 | – | Sell |
-104,000
| Closed | -$596K | – | 355 |
|
|
2018
Q3 | $596K | Buy |
+104,000
| New | +$595K | 0.04% | 215 |
|
|
2017
Q1 | – | Sell |
-157,700
| Closed | -$1.75M | – | 452 |
|
|
2016
Q4 | $1.75M | Sell |
157,700
-230,300
| -59% | -$2.17M | 0.12% | 182 |
|
|
2016
Q3 | $3.59M | Sell |
388,000
-108,547
| -22% | -$907K | 0.2% | 142 |
|
|
2016
Q2 | $3.15M | Sell |
496,547
-72,633
| -13% | -$482K | 0.16% | 141 |
|
|
2016
Q1 | $3.71M | Sell |
569,180
-10,820
| -2% | -$69.8K | 0.23% | 119 |
|
|
2015
Q4 | $4.7M | Buy |
580,000
+105,190
| +22% | +$786K | 0.49% | 80 |
|
|
2015
Q3 | $3.48M | Buy |
474,810
+69,810
| +17% | +$711K | 0.3% | 107 |
|
|
2015
Q2 | $4.15M | Buy |
+405,000
| New | +$4.48M | 0.25% | 108 |
|
J. Goldman & Co's FOMX Position: Q1 2020 in Review
J. Goldman & Co sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 168,778 shares — an estimated $562K sold.
J. Goldman & Co first reported a position in FOMX in Q2 2015 and held it in 11 quarters. The position peaked at $4.7M in Q4 2015. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- J. Goldman & Co reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- J. Goldman & Co sold 168,778 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $562K.
- J. Goldman & Co first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 11 quarters.
- J. Goldman & Co's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $4.7M in Q4 2015.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.